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Abstract
Lactobacillus rhamnosus GG (LGG) is one of the most widely used probiotic strains. Various health effects are well
documented including the prevention and treatment of gastro-intestinal infections and diarrhea, and stimulation of
immune responses that promote vaccination or even prevent certain allergic symptoms. However, not all
intervention studies could show a clinical benefit and even for the same conditions, the results are not univocal.
Clearly, the host phenotype governed by age, genetics and environmental factors such as the endogenous
microbiota, plays a role in whether individuals are responders or non-responders. However, we believe that a
detailed knowledge of the bacterial physiology and the LGG molecules that play a key role in its host-interaction
capacity is crucial for a better understanding of its potential health benefits. Molecules that were yet identified as
important factors governing host interactions include its adhesive pili or fimbriae, its lipoteichoic acid molecules, its
major secreted proteins and its galactose-rich exopolysaccharides, as well as specific DNA motifs. Nevertheless,
future studies are needed to correlate specific health effects to these molecular effectors in LGG, and also in other
probiotic strains.
Introduction
Lactobacillus rhamnosus GG (LGG), ATCC 53103 was
originally isolated from fecal samples of a healthy
human adult by Sherwood Gorbach and Barry Goldwin,
explaining its typical surname letters GG. It was identi-
fied as a potential probiotic strain because of its resis-
tance to acid and bile, good growth characteristics and
adhesion capacity to the intestinal epithelial layer [1].
Ever since, it has been one of the most widely studied
probiotic strains, used in a variety of commercially avail-
able probiotic products. The beneficial effects of this
strain have been studied extensively in clinical trials and
human intervention studies.
Probiotic bacteria are proposed to benefit human
health mainly by three general mechanisms of action
[2,3]. Firstly, certain probiotics can clearly exclude or
inhibit pathogens, either through direct action or through
influence on the commensal microbiota [2,4]. A second
mechanism is the capacity of certain probiotic strains to
enhance the epithelial barrier function by modulating
signaling pathways, such as nuclear factor-B (NF-kB),
Akt and mitogen- activated protein kinase (MAPK)-
dependent pathways, which lead to for example the
induction of mucus [5], or increased tight junction func-
tioning [6]. Thirdly, most probiotic strains can also mod-
ulate host immune responses, exerting strain-specific
local and systemic effects [7]. Many of the interactions
between probiotic bacteria and intestinal epithelial and
immune cells are thought to be mediated by molecular
structures, known as microbe- associated molecular pat-
terns (MAMPs), which can be recognized through speci-
fic pattern recognition receptors (PRRs) such as Toll-like
receptors (TLRs) [8].
Even though many experimental in vitro data and
experiments in animal models validate these mechanisms
for probiotic strains in general and for LGG in specific,
most published in vivo data in humans pay less attention
to mechanisms of action. Nevertheless, we believe that for
an optimized and more tailored application of probiotics,
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it is imperative to understand the mechanisms of interaction
with the host in great detail. LGG is an interesting model
probiotic strain, because of its wide use, its available genome
sequence [9] and the availability of numerous knock-out
mutants that allow the study of gene-function relations
[10-15]. In this review we aim to give an overview of the
recent advances in the molecular knowledge on LGG-host
interactions and try to provide a molecular framework for a
better understanding of the health effects of LGG.
Pili-mediated adhesive capacity of LGG
In vivo and in vitro evidence
One of the widely studied key features of LGG is its strong
adhesive capacity, which has been documented in vitro but
also in vivo in humans. LGG has been shown to be a very
good mucus adhering Lactobacillus strain compared to
related strains such as the dairy strain L. rhamnosus Lc705
and other probiotic strains such as L. johnsonii LJ1 and
L. casei Shirota [16] (Figure 1A). In human intervention
studies, LGG was also reported to persist longer and in
higher concentrations compared to closely related strains
such as L. rhamnosus LC705 [9]. Orally administered LGG
can be recovered from the feces at least one week after
administration in adults [9,17]. Of note, the colonization
capacity of LGG appears to be significantly better in new-
borns [18], which is related to reduced colonization resis-
tance exerted by a less established microbiota of infants
and which is probably a general feature for many probiotic
Figure 1 SpaCBA pili and the molecular mechanisms of adhesion. LGG is very good mucus adhering Lactobacillus strain compared to other
probiotic strains such as L. casei Shirota and L. johnsonii LJ1 and the closely related strain L. rhamnosus Lc705. Radioactively labeled bacteria
were allowed to adhere to isolated human intestinal mucus. The adhesion ratio (%) was determined by comparing radioactivity of bacteria
added to the radioactivity of bound bacteria after washing (A). Data were published before [16]. Presence of SpaCBA pili LGG cells based on a
TEM image of LGG labeled with SpaA antiserum and 10 nm protein A gold particles [26] (B) and on a AFM image of LGG in air [37] (C). The
predicted model of the pili shows a pilus backbone formed by the major subunit SpaA, as shown in the schematic figure. The minor subunit
SpaC is present on the tip and decorates the pilus over the length at ratio 1:2 with SpaA. The Spa B minor pilin serves as a molecular switch for
pilus termination and is bound to the peptidoglycan layer. However, it is suggested that leaky activity of the pilin-specific sortase can include
SpaB decorations on the pilus (D). Adapted from [26]. The SpaC pilin is thought to serve as a major adhesin of LGG. It can interact with other
SpaC molecules, inducing homophilic adhesion, and with intestinal epithelial cells or their extracellular matrix, in heterophilic adhesion. The exact
adhesion sites however remain unkown. Pili can have molecular spring properties which makes them capable to withstand shearing stress.
Moreover, the SpaC pilin decorated over the pilus length provide a molecular zipper mechanism that can facilitate a close interaction between
the host and the bacteria or bacteria with each other (E). Adapted from [35].
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strains. LGG can adhere to intestinal mucus [9,19] and
persist in the descending colon [20]. Colonic biopsies even
suggest that LGG colonization continues for longer than
indicated by fecal recovery [21]. LGG could also be recov-
ered from the tonsils [22], vagina [23] and oral cavity [24]
after probiotic therapy, but it does not seem as efficient as
other Lactobacillus strains in colonizing these niches.
LGG seems to show a preferential tissue tropism for the
intestinal mucus layer, although these findings could be
biased, as only limited studies have investigated the adher-
ence and colonization at other body sites.
Pili as key intestinal adhesins
A major breakthrough in our understanding of the
excellent adherence capacity of LGG was the discovery
of fimbria-like appendages [25], later named as pili [9].
Pili or fimbriae are long and thin proteinaceous protru-
sions of the cell surface present on specific Gram-
positive and Gram-negative bacteria. A genomic com-
parison with the closely related strain LC705 resulted in
identification of the spaCBA gene cluster involved in the
biosynthesis of the LGG-specific SpaCBA pili, and the
confirmation by Western blot and immunogold trans-
mission electron microscopy of structures of ca. 1 µm
that are around 5 nm thin (Figure 1B) [9]. Subsequently,
we found by mutational analysis of several predicted
adhesins that the SpaCBA pili play a key role in adhe-
sion to mucus, the Caco-2 intestinal epithelial cell line
and promote biofilm formation [14]. Of note, the LGG
genome also encodes another pili gene cluster, spaDEF,
but these pili do not seem to be expressed, at least not
under the tested conditions [9,14,26]. Interestingly, the
pili of Bifidobacterium breve UCC2003 appear to be
only expressed in the murine gastro-intestinal tract and
not in laboratory conditions [27], highlighting that con-
dition-dependent expression of the pili cannot be ruled
out. However, LGG remains piliated with SpaCBA pili
under different stress conditions such as bile salts and
low pH [28]. Recently pili were also found in various
other lactobacilli and lactococci [29-31]. Remarkably,
comparative genome and functional analysis of L. rham-
nosus species showed that functional SpaCBA pili are
significantly more prevalent in human isolates than in
dairy isolates. Moreover, the pili are most prevalent in
intestinal isolates, while none of the strains that origi-
nated from the oral and vaginal cavities were shown to
have functional pili [28]. Intriguingly, recent gut metage-
nomic studies also showed that pili genes form impor-
tant examples of highly abundant functions that could
be identified, even if mainly expressed by some low-
abundance microbes such as Echerichia coli, further
supporting a key role for mucus-binding pili in the
intestinal niche [32].
Structural properties of the SpaCBA pili
The LGG pilus contains three distinct pilin monomers
which are covalently linked in a sortase-dependent man-
ner: the major pilin SpaA and the minor pilins SpaB
and SpaC (Figure 1.D). Mass spectrometry revealed a
SpaA/SpaC/SpaB ratio of 5:2:1 [26]. As observed in
other Gram-positive pili, the major pilin SpaA exerts
merely a structural function forming the pilus backbone,
while the accessory pilins play a functional role [33,34].
The larger minor pilin SpaC, located on the tip of the
pilus and covering the pilus length [26], is thought to
play a pivotal role in adhesion to mucus. This was
shown using whole bacteria with a isogenic spaCBA
mutation [9], competitive blocking experiments with
SpaC antiserum [9], experiments with recombinant
SpaC in a mucus binding assay [9] and single molecule
atomic force microscopy (AFM) [35]. The smaller minor
pilin SpaB is thought to act as a molecular switch
responsible for pilus termination and initiation of pepti-
doglycan binding by the housekeeping sortase [26].
Another interesting feature of pili expression is the
presence of numerous insertion sequence (IS) elements
flanking the spaCBA operon in the LGG genome. It was
even suggested that the iso-IS30 element actually
enhances pili expression in LGG, while not in L. casei
strains [30]. It is however also possible that spontaneous
removal of the IS element would stop expression of pili
in LGG, although Douillard et al. [30] showed that LGG
could be recovered from various commercial products
with a very limited amount of genomic changes (2-3
SNPs) and was still capable of producing pili, indicating
its robustness under fermentation conditions. Neverthe-
less, others showed in a comparative genome analysis of
three LGG dairy product isolates that in two of these
strains, major stretches of genomic DNA were deleted,
including the spaCBA operon [36]. Moreover, LGG pili
are susceptible to shearing stress. Our AFM study
showed that bacterial cells subjected to 8000 × g centri-
fugal forces are completely devoid of pili [37]. As pili
seem to play an important role for the probiotic func-
tion of LGG, it is important for industrial production of
LGG that detrimental shearing stresses are avoided. The
presence of pili should be a key question for future
intervention studies with LGG.
Based on single molecule AFM, we could also suggest
that the LGG pili have two important nanoscale proper-
ties mediating interactions with the host (Figure 1.E).
Firstly, pili appear to function as nanosprings capable of
withstanding forces such as shearing stress. Secondly,
pili can function as a mechanical zipper [35]. As SpaC is
distributed not only at the tip, but also over the pilus
length [26], it is thought that a zipper-like mechanism
can facilitate a close interaction with the host after the
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first interaction is initiated by a SpaC subunit, enabling
other SpaC subunits along the tip, but also other cell
surface adhesins on the LGG surface to adhere step by
step, resulting in a more stable interaction. For instance,
two other LPxTG-like surface adhesins were found in
LGG: MabA as modulator of biofilm formation and
adhesion [13] and the mucus-binding factor MBF [38].
Possible immunomodulatory role of the SpaCBA pili
As key adhesive components, the immunomodulatory
capacity of the pili is also of high interest, although cur-
rent data are very limited. In a first study, focusing on
the nonpiliated spaCBA mutant of LGG, we could show
a ca. twofold increased induction of interleukin-8 (IL-8)
and other pro-inflammatory markers in intestinal
epithelial Caco-2 cells compared to wild-type, while a
mutant lacking exopolysaccharide (EPS) and showing an
increased exposure of SpaCBA pili resulted in ca. two-
fold less IL-8 mRNA induction [14]. In a more recent
study, Lactococcus lactis was genetically engineered to
express the LGG SpaCBA pili. These constructs
appeared to promote interaction with TLR2 and expres-
sion of IL-8 [39]. Moreover, in a comparison between
LGG and other commercial probiotic L. rhamnosus and
L. casei strains, it was shown that certain closely related
strains lacking pili expression have a reduced interaction
with TLR2 compared to LGG [28]. As part of our
ongoing research, we are investigating whether the pili
have a direct effect as MAMP interacting with PRRs,
such as TLR2, like has been shown for the type I pilus
of Streptococcus pneumonia [40], or whether they mainly
act indirect by mediating a close interaction with the
host cells and other LGG exposing surface-bound
ligands. Recent data suggest that it is not specifically the
presence or absence of SpaCBA pili that mediate
immune status. Rather, the pili appear to play an indir-
ect modulating role by promoting close interactions
with host cells such as epithelial cells, probably by the
zipper-like mechanism discussed above, so that other
effector molecules can exert their immune modulating
activities [14]. It will be very interesting to substantiate
this indirect immunomodulatory role in human volun-
teers, e.g. by intervention studies with spontaneous pili
mutants of LGG.
Lipoteichoic acid (LTA) as key immune effector
of LGG
One of the first effector molecules of LGG that were
studied are its lipoteichoic acid (LTA) molecules,
because LTA is considered as the Gram-positive equiva-
lent of Gram-negative LPS in stimulating strong
immune responses. However, the bio-active concentra-
tion of LTA is typically in de micromolar range, while
LPS is active in nanomolar concentrations [41].
Moreover, LPS and LTA interact with different PRRs.
The specific PRRs for LTA were shown to consist of
TLR2 in a heterodimer with TLR6 and co-receptors
CD14 and CD36 [42]. The structure of LTA of LGG
was shown by NMR to consist of a glycerolphosphate
backbone with D-alanyl esters (ca. 70%) as unique
detectable substituents and an average chain length
between n = 30 and n = 76. The glycolipid moiety con-
tains 2 fatty acid chains with an average length of C14,
with one double bound per fatty acid [12,43]. Analysis
of structure-activity relations showed the importance of
the lipid chains of LTA in LGG in interaction with
TLR2-6 and the induction of NF-B signaling [43].
To investigate the in situ role of LTA in live bacteria,
a mutant of LGG that showed a modified LTA structure
lacking D-alanine residues and an altered glycolipid
anchor, was created by mutating the dltD gene. This
gene encodes a membrane protein that facilitates the
ligation of the D-alanyl carrier protein with D-alanine
[12]. This mutant showed a strongly reduced interaction
with TLR2-6 and a lower induction of IL-8 mRNA in
the Caco-2 cell line compared to wild type, further sub-
stantiating a key role for LGG LTA in promoting more
pro- inflammatory responses [43]. Furthermore, the
dltD mutant significantly improved DSS- induced colitis
in treated mice compared to buffer control, while the
wild type strain showed actually detrimental effects in
that model [44]. Interestingly, similar effects were
observed with LTA mutants in other lactobacilli [45].
Complete removal of LTA in Lactobacillus acidophilus
NCFM [46] or a shift from mainly D-alanine to glucosyl
substitutions in Lactobacillus plantarum NCIMB8826
[47] also resulted in strains capable of more efficiently
alleviating inflammation. This shows that LTA is not an
LGG-specific effector molecule, but that it is an impor-
tant molecule in understanding Lactobacillus-host inter-
actions and is a crucial factor to take into account when
investigating anti-inflammatory effects.
Secreted proteins as probiotic effectors
In 2002, Yan and Polk showed that LGG promotes the
survival of intestinal epithelial cells (IECs) by preventing
cytokine-induced apoptosis through blocking of p38
MAP kinase. They found that the survival-promoting
effect was also present in other probiotic strains such as
L. acidophilus ATCC393 and L. casei ATCC4356, but
the strongest in LGG [48]. The supernatant of LGG was
shown to prevent apoptosis in IECs [49] and induce
heat shock proteins [50]. Consequently, two proteins
from the LGG supernatans were found to cause the
antiapoptic effect [49]. These proteins p75 (~75 kDa)
and p40 (~40 kDa) were later renamed as Major
Secreted Protein Msp1 and Msp2 respectively, because
of the discrepancy in molecular weight [15]. Each of the
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purified proteins was shown to activate the Akt signal-
ing peptide, inhibit cytokine-induced IEC apoptosis and
reduce tumor necrosis factor (TNF)- induced epithelial
damage. The proteins also promoted cell growth in
human and mouse colon IECs and cultured mouse
colon explants [51]. Moreover, they were shown to pro-
tect the intestinal epithelial barrier function from hydro-
gen peroxide-induced damage through blocking of MAP
kinases [52].
A subsequent in vivo mice study proved the efficacy of
recombinant Msp2/p40 delivered in a pectin/zein hydrogel
bead for the prevention and treatment of DSS- induced
intestinal injury and acute colitis and for ameliorating
colon epithelial cell apoptosis and chronic inflammation in
oxazolone-induced colitis [53]. Moreover, Msp2/p40 was
shown to cause phosphorylation of the epidermal growth
factor receptor (EGF-R) leading to activation of Akt. The
importance of EGF-R in the mechanism was confirmed in
the in vivo tests [53]. Nevertheless, the exact PRR could
not be identified. The activation of EGF-R is thought to be
indirect as Msp2/p40 was shown to stimulate the catalytic
activity of the metalloproteinase ADAM-17, which subse-
quently releases heparin-bound EGF in IECs, activating
EGF-R [54].
As mentioned before, Msp1/p75 and Msp2/p40 are
not unique for LGG. For instance, the homologous pro-
teins of L. casei BL23 can also cause EGF-R phosphory-
lation [55]. However, there exists some heterogeneity
between the homologues. Analysis of Msp1/p75 and
Msp2/p40 gene sequence showed homology with cell
wall hydrolases in LGG [51], but also in L. casei [55].
Msp1 was characterized in LGG as a D-glutamyl-L-lysyl
endopeptidase with an important role in daughter cell
separation [15]. Intriguingly, we could also show that
the Msp1 protein is glycosylated in LGG with Con-A
reactive residues [56], which could explain the apparent
discrepancy previously seen between the predicted mole-
cular weight and the molecular weight shown on Wes-
tern blot [51]. The serine-rich glycosylation site was not
found in homologues of Msp1 in several L. casei strains,
which suggest a species-specific glycosylation. The gly-
cosylation does not impede enzyme activity and was
suggested not to interfere with activation of Akt,
although a the glycan chain appears to have a modulat-
ing role as shield. The glycosylation seems to play a role
in increasing protein stability and protein binding to the
cell wall [56]. Interestingly, the ConA reactive S-layer
protein SlpA of L. acidophilus is suggested to be recog-
nized by DC-SIGN [57], although this remains to be
further substantiated. The Msp2 protein, on the other
hand, appears not to be glycosylated. The exact function
of LGG Msp2 remains unclear since its hydrolytic pepti-
doglycan (PG) degrading activity is limited and an msp2
knock-out mutant could not be constructed, possibly
because of its essential role in LGG. Immunofluores-
cence analysis suggests a possible role in early stage cell
septum formation [15].
Because of their action as PG hydrolases, it also
remains to be studied whether Msp1 and Msp2 could
have immunomodulatory functions by release of PG frag-
ments. Intriguingly, a recent study showed that PG might
be a central mediator for the beneficial effect of certain
probiotic lactobacilli, such as Lactobacillus salivarius
Ls33 in inflammatory bowel disease with NOD-2 as a key
receptor [58]. Although the PG of most lactobacilli share
the same basic structure, the PG molecules of this Lacto-
bacillus strain was shown to contain an additional muro-
peptide, MurNAc-l-Ala-g-d-isoGln-l-Lys, which was
suggested to be the NOD2 ligand displaying anti-inflam-
matory properties [59]. The PG structure of LGG was
previously determined when analyzing the PG hydrolyz-
ing activity of Msp1/p75 [15]. It is at present not known
whether LGG PG contains such strong NOD2 ligands
and how this NOD2 interaction could be influenced by
its collection of PG hydrolases.
Exopolysaccharides (EPS) as modulating
adaptation factors
An extracellular polysaccharide (EPS) layer is commonly
found in lactobacilli. Of interest, EPS molecules show a
large structural diversity [60], so that they are clearly
strain-specific molecules. The LGG cell surface appears
to contain two major types of polysaccharides: long
galactose-rich polysaccharides and shorter glucose/man-
nose-rich polysaccharides [61]. We could yet identify the
operon responsible for galactose-rich EPS synthesis [62].
A knock-out mutant of the welE gene, encoding the
priming glycosyltransferase, is completely devoid of the
long galactose-rich EPS but shows a higher concentration
of short glucose-rich EPS [62]. This mutant shows an
increased adhesion to Caco-2 IECs, linked to increased
exposure of the SpaCBA pili [14,62]. In addition, this
type of galactose-rich EPS appears to be an important
adaptation factor for LGG as the welE mutant shows a
reduced in vivo survival in the murine gastrointestinal
tract (GIT) [63]. More specifically, the long galactose-
rich EPS were shown to protect the cell against comple-
ment-mediated lysis and cathelicidins, specific cationic
antimicrobial peptides [63]. It thus seems important that
this type of EPS production is balanced between optimal
protection and optimal adhesion.
The role of EPS in the interaction between LGG and
the host remains largely unclear. Results obtained in our
lab indicate that isolated galactose-rich EPS are not
principal inducers of cytokines in the Caco-2 intestinal
epithelial cell line [14]. On the other hand, isolated EPS
from LGG appears to counteract the cytotoxicity of
Bacillus cereus on Caco-2 cells and of streptolysin-O on
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rabbit erythrocytes [64]. However, as low concentrations
of the major secreted proteins have an anti-apoptotic
effect in IECs [51], it remains to be ruled out that pro-
tein contaminants in the purified EPS are not interfering
with the results. In addition, the role of the other glu-
cose-rich type of EPS from LGG remains to be substan-
tiated. A recent network based in silico analysis of the
glycosyltranferase genes of LGG could identify the puta-
tive gene cluster involved in their biosynthesis [65],
which opens perspectives for functional analyses with
mutants.
Apart from EPS, other genes and molecules play a role
as factors that promote the adaptation of LGG to the
human host and gastro-intestinal tract in particular. For
instance, an elegant study combining transcriptomics
and proteomics in LGG identified putative adaptation
factors involved in the bile stress response of LGG.
Among the identified functions were general stress
responses as well as cell envelope-related functions,
including pathways affecting fatty acid composition, cell
surface charge, and thickness of the EPS layer [66]. Our
recent recombinase-based in vivo expression technology
(R-IVET) experiment, similar as in L. plantarum
WCFS1 [67], also indicated a remarkable metabolic flex-
ibility of LGG in the murine gastro-intestinal tract
(Sarah Lebeer et al., in preparation).
Secreted antimicrobials produced by LGG
Several in vitro studies have shown the efficacy of LGG
against the viability, adherence or infection of GIT patho-
gens. Indeed, LGG was shown to reduce the viability of
Salmonella enterica subsp. enterica serovar Typhimur-
ium [68-72], Shigella sonei [73], and Pseudomonas,
Staphylococcus and Streptococcus strains [70] in vitro. In
vivo mice experiments confirmed that LGG pretreatment
reduces S. Typhimurium infection parameters [74]. How-
ever, there is some controversy concerning the results
obtained with S. Typhimurium, as not all studies could
detect a reduction in viability [74,75] or reduced adher-
ence to human intestinal mucus [75,76]. Unfortunately,
to our knowledge no human trials have been carried out
focusing on Salmonella specifically.
There have been a number of studies trying to identify
the antibacterial compounds, mostly focusing on
S. Typhimurium. LGG grown in de Man-Rogosa-Sharpe
(MRS), a medium recommended for lactobacilli, was
shown to inhibit growth of S. Typhimurium SL1344 in a
pH-dependent manner [76]. Interestingly, lactic acid was
identified as the main antimicrobial compound in differ-
ent conditions [69,71,72], which is clearly not a specific
factor for LGG. As lactic acid permeabilizes the Gram-
negative outer membrane, it might facilitate antibacterial
action of other compounds, such as organic acids or
bacteriocins [77]. These compounds might indeed
participate as a recent study showed that the antimicro-
bial effect appears not to be dependent on lactic acid
concentration alone [68]. Seven heat-stable peptides
with antibacterial activity against enteroaggregative
E. coli strain EAEC 042, Salmonella Typhi, and Staphy-
lococcus aureus were identified in LGG culture medium
[78]. Unfortunately, these peptides have not yet been
identified, to the best of our knowledge. Of note, the
genome sequence of LGG encodes several bacteriocin-
related genes [9]. Despite several attempts, we and
others were not yet able to shown bacteriocin produc-
tion under laboratory conditions and coculture with
possible inducing strains, although a bacteriocin locus
was found to be induced in the murine gastro-intestinal
tract after R-IVET (Sarah Lebeer et al., in preparation).
Bacterial cell-cell communication through quorum sen-
sing (QS) might also interfere with pathogen infection as
strains present in the gut microbiota are thought to com-
municate to coordinate adaptive processes such as com-
petition and cooperation for nutrients and adhesion sites
[2]. LGG was reported to produce autoinducer-2 (AI-2),
which is suggested to be an important interspecies QS
molecules, produced by both Gram-positive and Gram-
negative bacteria [79]. However, the role of QS in patho-
gen exclusion is difficult to investigate since the AI-2
synthase LuxS also interferes with the cell metabolism.
Indeed, a luxS knock-out mutant of LGG was shown to
have numerous pleiotropic effects, which could not be
complemented by exogenous addition of synthetic AI-2
molecules [10]. It remains to be investigated whether
AI-2 or other QS systems play a role as a probiotic
mechanism for LGG. For instance, McCormick and col-
leagues could nicely show that cyclic dipeptides of strain
Lactobacillus reuteri RC-14 quench agr-mediated expres-
sion of toxic shock syndrome toxin- 1 in staphylococci
[80], highlighting that QS could play a role in antipatho-
genic mechanisms of probiotics.
Unmethylated CpG-rich DNA motifs as
intracellular MAMPs
Other important bacterial MAMPs are derived from
bacterial DNA and become only available after cell lysis.
Bacterial DNA can be distinguished from eukaryotic
DNA in frequency of unmethylated cytosine-guanine
dinucleotides (CpG) motifs. These CpG motifs are rela-
tively widespread in viral and bacterial DNA, but are
not common in mammalian DNA. CpG motifs and syn-
thetic unmethylated CpG oligonucleotide mimics
(ODN) are generally recognized by TLR9 and can
induce a strong T-helper-1 (TH-1) like inflammatory
response [81]. Targeting TLR9 with CpG or ODN has
been a strategy for a number of clinical trials studying
the effect on cancer treatment, allergy and infection dis-
eases, reviewed in [82]. It is important to note that
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TLR9 function in the intestinal epithelial layer is
thought to be polarized as IECs respond differently to
apical or basolateral exposure to CpG. As basolateral
TLR9 activation signals activation of the NF-B path-
way, apical TLR9 stimulation seems to prevent NF-B
activation. This mechanism is thought to play an impor-
tant role in epithelial homeostasis [83].
A bioinformatic analysis of the frequency of CpG
motifs in the genomes of gut commensals demonstrated
a correlation with genomic GC content [84]. Indeed, in
vitro treatment of polarized IEC layers showed that
DNA form different probiotic strains have differential
effects on NF-B activation [85] and in vivo studies
using a mouse model showed differential effects on
immune proliferation activity [86]. The genome of LGG,
but also of other lactobacilli such as L. plantarum
WCFS1, appears to have a higher frequency of the opti-
mal motif for interaction with TLR9, i.e. GTCGTT, than
could be expected by their genomic GC content [84].
Moreover, a potent ODN, TTTCGTTT named ID35,
was identified in the LGG genome [86]. The effect of
chromosomal DNA of LGG was also tested in polarized
IECs, where it was shown to diminish TNF-induced NF-
B activation and reduction of trans- epithelial resistance
thus protecting the epithelial layer [87]. The chromoso-
mal DNA of LGG and derived ODNs were also shown to
be strong in vivo inducers of murine B cell proliferation
and were able to stimulate TH1 immunity in murine sple-
nocyte cells [86]. ID35 isolated form LGG genome even
seems to be beneficial in allergy prevention in an ovalbu-
min-sensitized mouse model, by inducing the TH1-
response and suppressing ovalbumine-specific IgE pro-
duction [88]. Moreover, a study using peripheral blood
mononuclear cells (PBMCs) from allergic patients
showed that LGG as well as its genomic DNA can modu-
late the TH1/TH2 response to specific allergens dose-
specifically. More than 50% of the effect of LGG could be
explained by the effect of the genomic DNA, as stated by
the authors [89].
Profiling of host responses against LGG
The above mentioned LGG molecules and their corre-
sponding mutants are studied one-by- one but it should
be highlighted that in situ the host interaction towards
LGG will be an integrated sum of different interactions.
A combination of all MAMP-PRR interactions decides
how the immune system is triggered, while also various
metabolites such as lactic acid can be envisaged to modu-
late host responses. Therefore, molecular profiling of the
host responses upon LGG application can reveal impor-
tant novel insights (Figure 2), especially if time course
studies are included. Until now, these host responses
towards LGG have been mainly characterized by tran-
scriptomics methods, but also other approaches such as
proteomics and metabolomics show great potential, espe-
cially if methods are integrated and combined with net-
work biology approaches [90]. For instance, a gene
expression analysis of the small bowel mucosa from
patients treated with LGG compared with placebo treat-
ment, showed that LGG affected genes involved in
immune response and inflammation, apoptosis, cell-cell
signaling, cell growth and cell differentiation, cell adhe-
sion and signaling. It should be noted that these analyses
were done at a rather late time point, i.e. in biopsy sam-
ples of patients consuming LGG during one month
(1.2 × 1010 colony forming units, CFU, daily) [91]. A
more recent in vivo transcriptome analysis compared the
mucosal responses towards LGG (1.68 × 1010) with two
other commercially available lactobacilli (i.e. L. acidophi-
lus Lafti-L10, L. casei CRL-431) in a placebo-controlled
randomized double-blind cross-over design in which the
volunteers consumed all three probiotic preparations and
a placebo control in a randomized order with each time a
2-week wash-out period. Interestingly, even after only
6 h, the mucosal response to LGG was also mainly char-
acterized by the induction of TH1 development via the
IFN-STAT4 (signal transducer and activator of transcrip-
tion 4) axis and affected pathways include cellular growth
and proliferation pathways, wound healing, angiogenesis,
interferon mediated responses, calcium signaling and ion
homeostasis [92]. These pathways contain signatures of
the previously documented activity of Msp1/p75 and
Msp2/p40 to promote cell proliferation and epithelial
integrity [51,53,54], but clearly other factors play a role.
The same method was also used to investigate whether
humans respond differently to different growth stages of
L. plantarum WCFS1 [93]. They indeed observed clear
differences in the transcriptional response to exponen-
tially growing or stationary phase bacteria, and
between viable and heat-killed stationary bacteria. It
will be very interesting to use the same analyses to
investigate the transcriptional responses towards LGG
wild type and spontaneous non-GMO food-grade
mutants, such as spontaneous pili mutants, to explore
their relative contribution to the human host response.
Alternatively, experiments with dedicated isogenic
mutants such as of Msp1/p75 [15] could be designed
for analyses in animal models, since Lin et al. [94]
have also nicely shown by transcriptomics that LGG
also upregulates cytoprotective gene expression and
MAPK-related expression in the developing murine
intestine. In addition, ex vivo and in vitro models such
as the porcine small intestinal epithelial cell line
(IPEC-J2) appear to be good models for the study of
innate immune responses to probiotics [95].
Nevertheless, and probably most importantly, the
abovementioned duodenal transcriptome studies of
Kleerebezem and coworkers showed a remarkable large
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distance of the transcriptome profiles between the
human participants. As all participants were healthy,
the large inter-person variation indicates that mucosal
tissues have multiple mucosal solutions to accomplish
healthy homeostasis, which is suggested to be a
molecular “bandwidth of human health” [96]. Clearly,
this complicates the selection of the most appropriate
biomarkers to monitor probiotic intervention in
human study subjects and the possibility for stratifica-
tion of responders and non-responders.
Figure 2 Molecular interactions of LGG with intestinal epithelial cells. LTA as a MAMP interacts with TLR2-6, activating NF- signaling [43].
Secreted protein Msp2/p40 induces release of HB-EGF that causes phosphorylation of EGF-R, activating downstream protein kinase C (PKC) and
phosphoinositide 3-kinase (PI3K) -Akt signaling [51,53,54]. A recent human duodenal transcriptome study indicates that JUN and STAT4
transcription factors play a central role in downstream signaling after consumption of LGG, leading to mainly TH1 cytokine production and
activating pathways involved in cellular growth and proliferation, wound healing, angiogenesis, interferon-mediated responses, calcium signaling
and ion homeostasis [92]. Adapted from [96]
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Clinical benefits of LGG
In the next paragraphs, we tried to summarize some
well documented clinical benefits and explain some of
the findings with the molecular framework we provided
above, although this association should be taken with
caution.
Promotion of gastro-intestinal health in children and
adults
As mentioned before, LGG has been shown to colonize
the gut of newborns significantly better than adults [18].
Interestingly, prenatal supplementation with LGG
(1.8×1010 CFU in capsules, daily from 36th week of
gestation) has been reported to change the composition
of the neonates microbiota, promoting a beneficial pro-
file dominated by bifidobacteria [97,98], although the
overall microbial diversity did not seem to have changed
[99]. Others showed that postnatal application of LGG
(109 CFU daily, lyophilized powder mixed with breast
milk) appears to affect neonatal intestinal colonization
patterns causing a higher species diversity compared to
placebo [100], although the analysis was not done at
detailed level. How exactly LGG could promote the
colonization of bifidobacteria in vivo remains to be
further explored.
Given its excellent intestinal mucus adherence capaci-
ties, LGG has also been often selected as candidate pro-
biotic for the prevention and treatment of gastro-
intestinal infections and diarrhea, although the efficacy
is not uniformly proven. Three subsequent meta-analysis
studies have discussed the use of LGG for the treatment
of acute diarrhea in children [101-103]. Overall, the cur-
rent data suggest that LGG can reduce the duration of
diarrhea with 1.05 days, particularly in children from
geographical Europe, treated with a high dose of LGG
(≥1010 CFU/day). LGG (109 CFU daily in fermented
milk product) was also shown to reduce the risk of
acquiring nosocomial gastrointestinal infections when
administered daily in hospitalized children [104]. Under-
nourished Peruvian children showed a lower incidence
of diarrhea when treated with LGG (>1010 CFU daily,
lyophilized powder mixed with liquid cherry gelatin).
Effects were the largest in non-breastfed children [105].
However, long-term consumption of milk containing
LGG (108 CFU daily) in children attending day care cen-
ters in Finland could not show an effect on the inci-
dence of gastro-intestinal symptoms [106]. It is
important to note that the unsuccessful trial tested a
100-fold lower daily concentration, although other fac-
tors such as probiotic formulation and study subject
heterogeneity could of course also play a role. A recent
meta-analysis concluded that LGG treatment can also
reduce pain frequency and intensity in children with
abdominal pain-related disorders, particularly among
irritable bowel syndrome (IBS) patients. However, it is
important to mention that the clinical effects were sig-
nificant but moderate [107], which is not unexpected if
you consider the large subject heterogeneity in IBS
patients.
In other conditions, LGG effects were better stratified.
For instance, oral supplementation with LGG (6 × 109
CFU with human milk) has been shown to prevent
enteric colonization by Candida species in preterm neo-
nates in a randomized study [108], although the under-
lying mechanisms need to be explored. Two pilot
studies also showed promising results for LGG treat-
ment (respectively 1010 CFU in skim milk and 1.2 × 109
CFU in lyophilized powder daily) of recurrent Clostri-
dium difficile induced colitis in children [109,110], but
this should be repeated in larger trials. Furthermore,
application of a commercial yoghurt with LGG to renal
patients during 8 weeks has been shown to succeed in
clearing vancomycin-resistant enterococci in all patients
in an double-blind, randomized, placebo-controlled trial
[111]. A larger single-blind, randomized, placebo-con-
trolled trial focused on children (3 × 109 CFU daily, dis-
solved in water or milk) and could show a significant
difference between the treated and the control groups
only after three weeks [112]. The mechanism of clearing
of this vancomycin-resistant enterococci remains to be
explored, but the SpaCBA pili of LGG share some
sequence identity (30-40%) with the pili of Enterococcus
faecalis and Enterococcus faecium [9]. Clearly, experi-
ments with non-GMO pili deficient variants of LGG
would be highly interesting to study their role in the
gastro-intestinal and pathogen exclusion effects of LGG.
Possible effects at other body niches
Although many intervention studies with LGG are tar-
geting the GIT, it is also interesting to investigate extra-
intestinal effects of LGG. For instance, LGG has been
shown to reduce oral counts of Streptococcus mutans, a
bacterium correlated with caries formation, respectively
in yogurt, milk and lozenges [113-115]. Especially long-
term consumption of LGG containing milk (5-10 × 105
CFU) appears to be able to reduce caries development
in children [114]. Of note, there was no effect of short-
term consumption of LGG (4×108 CFU daily) on the
acidogenicity of plaque nor on caries formation in
adults, although it should be noted that LGG was admi-
nistered in a tablet, which might not be the best formu-
lation [116]. Importantly, LGG appears not to ferment
sucrose to a significant level [9], indicating that it is
itself not cariogenic, a property which is sometimes
attributed to lactobacilli due to lactic acid production.
Others have investigated the effect of LGG consump-
tion on respiratory health. For instance, Hojsak and col-
leagues [104] showed that fermented milk containing
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LGG was efficient in reducing the risk on respiratory
tract infections (RTIs) that lasted longer than three days
in hospitalized children. Also, preterm infants treated
daily with 109 CFU LGG in capsules starting within one
week after birth, appear to have significantly lower inci-
dence of RTIs and rhinovirus-induced episodes in the
first 2 months [117]. Furthermore, capsulated LGG (109
CFU) was shown to protect hospitalized patients against
ventilator-associated pneumonia, mainly when caused by
Gram-negative pathogens like Pseudomonas aeruginosa
[118]. Moreover, in cystic fibrosis patients colonized
with P. aeruginosa, long-term LGG treatment (6×109
CFU daily, in oral rehydration solution) significantly
decreased the incidence of pulmonary exacerbations and
increased body weight [119]. Unfortunately, this study
did not evaluate P. aeruginosa colonization status after
LGG treatment. Clearly this area requires further
research, because probably a combination of LGG’s anti-
pathogenic and immune modulating capacities deter-
mines its potential in RTIs.
Immunomodulatory applications of LGG
Allergic diseases
The potential immunomodulatory effects of LGG that
have yet received most attention include its widely dis-
cussed effects against allergic disease. In a study pub-
lished in The Lancet, Kalliomäki and colleagues
[120-122] showed that the combination of prenatal
maternal (2-4 weeks) and postnatal pediatric (6 months)
LGG treatment (1010 CFU daily, capsules or in water) in
families with a history of atopic disease, significantly
lowered the risk of eczema at the age of 2, 4 and 7.
However, allergic rhinitis and asthma tended to be more
common in the LGG treated group and no significant
differences were found in incidence of cow milk allergy.
Moreover, Kopp and colleagues [123] could not repeat
the beneficial results against eczema using a similar pro-
tocol and concentration. The reason for these different
outcomes is unknown, however it is thought that the
different genetic background of the tested populations
(Finnish versus German) might play a role. Also, the
German trial had more infants with older siblings,
which could be a potential cofounder [120,123]. In addi-
tion, it seems that different probiotic products have
been used for these studies, so that also differences in
probiotic formulation, and for instance pili presence,
cannot be ruled out.
Atopic dermatitis in children could not be treated by
LGG in three independent trials, using a daily concen-
tration of 5×109 CFU/100 ml formula [124], 5×109 CFU
in milk [125] or 1010 CFU in milk [126]. However, in
these trails there was a consistent but not significant
effect of LGG in the IgE-sensitized subgroup. Two other
trials also reported that treatment (5×109 CFU daily in
milk) was efficient in IgE-sensitized infants, but not in
non-IgE-sensitized infants [127,128]. This is probably a
good example that patient stratification is important to
identify potential responders, but more research is
necessary to determine the effect of LGG in IgE-sensi-
tized infants.
Related to food allergy, it was reported that adminis-
tration of capsulated LGG (5×109 CFU) in infants with
cow’s milk allergy augments IFN-g production in stimu-
lated PBMCs, thus possibly providing beneficial TH1
immunomodulatory signals [128]. Indeed, infants
acquire more oral tolerance when hydrolyzed casein for-
mula was administered in combination with LGG (107
CFU/ 100 mL) than with the formula alone [129]. In
milk-hypersensitive adults, LGG (2.6×108 CFU daily in
milk) has been shown to reduce the immunoinflamma-
tory response by reducing the expression of specific
receptors such as the complement receptors CR1 and
CR3 [130].
LGG as a vaccine adjuvant
Another perhaps more elegant way to investigate the
immunomodulatory effects of LGG is by studying its
capacity to ameliorate humoral responses to vaccines
when applied as an adjuvant. One study showed that the
immunogenicity of an oral rotavirus vaccine was signifi-
cantly ameliorated when mixed with 5×1010 CFU of
LGG [131]. LGG in milk (1010 CFU daily, 1 week before
vaccination, 4 weeks after) was also shown to increase
the poliovirus neutralizing antibody titer with a fourfold
increase in poliovirus-specific IgA in adults receiving an
oral vaccine against polio 1, 2 and 3 [132]. Moreover,
LGG treatment (1010 CFU in a capsule, daily, 28 days
starting at vaccination) increased protection rates after
an oral life attenuated influenza vaccine. The effect was
viral strain-dependent as antibody titers against H1N1
and B strains were low for placebo and LGG-treated
groups. For the H3N2 strain, LGG increased protection
significantly [133]. However, there was no influence on
the effect of an oral S. Typhi Ty21a oral vaccine (4×1010
CFU daily, 7 days) [134]. In addition, a recent study
even showed that maternal supplementation with LGG
(1.8 × 1010 CFU daily) from 36 weeks gestation until
delivery reduces vaccine-specific immune responses for
tetanus, Haemophilus influenzae type b (Hib) and pneu-
mococcal conjugate (PCV7) vaccines in infants at high
risk of developing allergic disease [135], indicating that
the timing of administration is important if one desires
an adjuvant effect and that LGG might not always be
the best choice for these purposes. Moreover, van Baar-
len et al. [92,93] showed other lactobacilli such as L.
plantarum WCFS1 show a more clear modulating of
the NF-B pathway.
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Conclusions
Is LGG a better probiotic strain than other probiotics on
the market? This question is difficult to answer, since
the answer largely depends on the host response that is
aimed for by the application. As mentioned before, the
host response is dependent on the combination of sev-
eral bacterial effectors, including MAMPs interacting
with PRRs. Even though these effectors might not be
unique for LGG, it seems that the sum of effectors in
LGG is often beneficial for the host, while strains with
similar MAMPS might show different results. Small var-
iations in structure (pili, LTA, EPS, etc.), expression
level or ratio can also have a large effect on the host
response. However, it is also apparent that not all
reported health effects of LGG are univocal. Successful
administration appears to depend on the applied dose,
growth phase, formulation, time of administration, dura-
tion of treatment, age and genetic background of study
subjects, among other variables (Figure 3). Nevertheless,
one of the clear advantages of LGG is that this probiotic
Figure 3 Pipeline for the design of intervention trials with LGG and related probiotics. In this schema, we have made an overview of
different steps that should ideally been taking when designing novel intervention studies with LGG or related probiotics, taking current
information into account. For more information, the reader is referred to the main text of this manuscript.
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is well characterized and so widely used that it has a
very good safety track record. LGG has been consumed
in over 40 countries worldwide and is especially popular
in Finland with a yearly per capita consumption rate of
6L in 2000 [136]. To support the safety of LGG, it was
shown that despite increasing LGG consumption in Fin-
land and Sweden respectively, the rate of Lactobacillus
bacteremia remained constant [137,138]. Moreover, the
use of LGG in a wide variety of clinical trials without
serious adverse events confirmed its safety. LGG has
been administered to, among others, low birth weight
infants [139,140], pregnant women [122,123,141], HIV-
infected patients [138] and patients with a mechanical
ventilator [118].
Nevertheless, case reports show that probiotic therapy
is to be discouraged in certain groups of patients. In a
review concerning the safety of probiotics, it was con-
cluded that adverse effects of probiotics were correlated
with (i) impaired intestinal barrier function, (ii) immune
compromised state and (iii) central venous catheter
[142]. Indeed, cases specifically reported for LGG show
that these risk factors might play a role. For instance, a
number of infants treated with LGG for short gut syn-
drome associated with intestinal friability seemed to
manifest sepsis with LGG-like bacteria [143,144] and an
ulcerative colitis patient was diagnosed with LGG bac-
teremia [145], although these identifications were not
done at a detailed genomic level. Nevertheless, in
patients with a seriously compromised integrity of the
barrier function of the intestine, the administration of
specific LGG molecules is probably a better strategy
than living LGG cells, because of the risk for transloca-
tion of the bacteria from the intestines into the blood.
Taken together, the various clinical trials that have yet
been published with LGG, notwithstanding their out-
come, will help the design of novel trials, while also the
recent molecular data on the genes and molecules of
LGG that could be important for its probiotic function
will lead to better clinical trials and better substantiation
of potential modes of actions. This will go hand in hand
with the ongoing developments of omics technologies
(metagenomics, transcriptomics, metabolomics, detailed
sequencing of spontaneous mutants of LGG) to monitor
the impact of LGG application and to go towards a bet-
ter understanding of responders and non-responders.
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